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Abstract: Aberrant function of Smad2, a crucial member of transforming growth factor beta (TGF-β)
signaling, is associated with the development of malignancies, particularly in the gastrointestinal
district. However, little is known about its possible prognostic role in such tumor types. With the first
meta-analysis on this topic, we demonstrated that the lack of the activated form of Smad2
(phosphor-Smad2 or pSmad2), which was meant to be the C-terminally phosphorylated form,
showed a statistically significant association with an increased risk of all-cause mortality in patients
with gastrointestinal cancers (RR, 1.58; 95% CI, 1.05–2.37, p = 0.029, I2 = 84%), also after having
adjusted for potential confounders (RR, 1.65; 95% CI, 1.24–2.18; p < 0.001; I2 = 4%). This finding
highlights the importance of the TGF-β signaling in this type of cancer. In this line, further studies
are needed to explore more in depth this important molecular pathway, focusing also on potential
therapeutic strategies based on its effectors or molecular targets.
Keywords: Smad2; TGF-β; pSmad2; phosphorylation; signaling
1. Introduction
Transforming growth factor beta (TGF-β) signaling plays an essential role throughout
development and later in adult homeostasis, interacting and coordinating different cell mechanisms.
Notably, biological activities of TGF-β initiate with its binding to a heteromeric complex of two
types of transmembrane receptors, namely type I and type II receptors; TGF-β occupancy induces
an association between the type I and II receptors, causing the phosphorylation of the type I receptor
by the constitutively active type II receptor [1–6]. The phosphorylated type I receptor then triggers
activation of important cofactors, namely Smad2 and Smad3, by phosphorylating their C-terminal
serine residues. Activated Smad2 and Smad3 form heteromeric complexes with Smad4 and other
mediators, and translocate into the nucleus, forming a transcription complex with other cofactors, as well
as participating also in the expression of target genes [1–6] (Figure 1).
Aberrant function of members of the TGF-β superfamily is associated with a wide range of human
diseases, including cancer. Particularly, alterations in the activation of the protein Smad2, which is
the product of the homonymous gene located on the q21.1 of the chromosome 18 (genomic location:
Int. J. Mol. Sci. 2019, 20, 3831; doi:10.3390/ijms20153831 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 3831 2 of 11
chr18:47,808,957-47,931,193; www.genecards.org, last access 07/22/2019), appear very important in
tumorigenesis [7–12].
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 2 of 10 
 
location: chr18:47,808,957-47,931,193; www.genecards.org, last access 07/22/2019), appear very 
important in tumorigenesis [7–12].  
 
Figure 1. Schematic representation of the complex interactions involving TGF-β signaling and other 
important pathways in gastrointestinal tumors. 
The most important effect of TGF-β mediated by pSmad2 in cancer regards the loss of the role 
of tumor-suppressor, with a change to a pro-tumorigenic action for tumor progression. The pro-
cancer progression consequences of aberrant TGF-β pathway signaling involves stromal remodeling, 
promotion of tumor cell plasticity (facilitating migration, invasion and metastasis), neo-angiogenesis 
and immunosuppression with loss of immunosurveillance [7–12]. pSmad2 expression is commonly 
used to describe the degree of TGF-β signaling activation, and nuclear pSmad2 is considered a good 
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investigated with immunohistochemistry (IHC), using different cut-off levels in varying studies to 
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tumorigenesis activating the epithelial-to-mesenchymal transition [17]. This dual role of TGF-
β/Smad2 pathway renders its comprehension as a possible prognostic moderator in cancer more 
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pathway is very important, among others, in gastrointestinal cancers [10–12], we decided to study 
the possible prognostic role of Smad2 in this type of tumor with the first systematic review and meta-
analysis on this topic. 
2. Results 
2.1. Search Results 
Figure 1. Schematic representation of the complex interactions involving TGF-β signaling and other
important pathways in gastrointestinal tumors.
The most important effect of TGF-β mediated by pSmad2 in cancer regards the loss of the role of
tumor-suppressor, with a change to a pro-tumorigenic action for tumor progression. The pro-cancer
progression consequences of aberrant TGF-β pathway signaling involves stromal remodeling,
promotion of tumor cell plasticity (facilitating migration, invasion and metastasis), neo-angiogenesis
and immunosuppression with loss of immunosurveillance [7–12]. pSmad2 expression is commonly
used to describe the degree of TGF-β signaling activation, and nuclear pSmad2 is considered a good
marker of activated TGF-beta signaling [13]. The expression of nuclear pSmad2 has been mainly
investigated with immunohistochemistry (IHC), using different cut-off levels in varying studies to
establish absent, low or high expression [13–16].
However, to further complicate the TGF-β landscape, recent evidence has indicated that
the activation of this signaling pathway via Smad2, above all in late stages tumors, may promote
tumorigenesis activating the epithelial-to-mesenchymal transition [17]. This dual role of TGF-β/Smad2
pathway renders its comprehension as a possible prognostic moderator in cancer more difficult.
Moreover, the literature lacks a comprehensive summary on this topic. Given that this pathway is
very important, among others, in gastrointestinal cancers [10–12], we decided to study the possible
prognostic role of Smad2 in this type of tumor with the first systematic review and meta-analysis on
this topic.
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2. Results
2.1. Search Results
Altogether, 1197 non-duplicated articles were identified through the literature search.
After excluding 1171 articles based on title/abstract review, 26 articles were retrieved for full text review
and, following the application of the inclusion criteria, six unique articles were considered as eligible
for the meta-analysis (Figure S1) [18–23].
2.2. Study and Patient Characteristics
The studies included in this meta-analysis regarded patient-cohorts from Asia (four studies) [18–20,22]
or Europe (two studies) [21,23] and were equally divided among the most important gastrointestinal
cancers, investigating indeed esophageal tumors (two studies) [18,19], gastric cancer (two studies) [20,22],
and colorectal cancer (two studies) [21,23] (Table S1).
Altogether, the studies followed-up 890 patients, 393 (44.2%) of which were pSmad2-. The mean
Newcastle-Ottawa Scale (NOS) score was 8.5 points (range: 8–9), with no manuscript considered
as at high risk of bias (Table S2). All studies reported adjusted analyses, but for one the specific values
of pSmad2 after multivariable analysis were not available [18]; the median number of confounders
considered in the multivariate analysis in the remaining studies was 6.4 (Tables S1 and S3). There were
no statistically significant differences between pSmad2− and pSmad2+ groups of patients regarding
gender, TNM stage or tumor grading. All data presented in this meta-analysis were derived from
studies that have taken into account only the C-terminally phosphorylated Smad2.
2.3. Association between pSmad2- and pSmad2+ and Survival
Pooling data from five studies [18–22], there was an increased risk ratio (RR) of all-cause mortality
in patients with pSmad2-, which was statistically significant (RR, 1.58; 95% CI, 1.05–2.37, p = 0.029,
I2 = 84%) (Table 1).
Table 1. Risk ratios (unadjusted and adjusted) for all-cause mortality (ACM) of patients with
gastrointestinal cancers, based on pSmad2- vs. pSmad2+ status.
Parameter NStudies
Risk Ratio
(95% CI) p Value
Heterogeneity
(I2%); tau2
Egger Test ± SE
(p Value)
Unadjusted 5 1.58(1.05–2.37) 0.029 84%, p < 0.0001 8.62 ± 12.51 (p = 0.54)
Adjusted 5 1.65(1.24–2.18) <0.001 4%; p = 0.38 −2.28 ± 2.83 (p = 0.48)
Abbreviations: ACM: All-cause mortality; CI: Confidence intervals; SE: Standard error.
This association has also been highlighted by a forest-plot (Figure 2).
In five studies reporting available adjusted data from multivariate analysis [19–23], after adjusting
for a median of five covariates (range: 5–8) (Table S3), pSmad2- carried a significantly higher risk
of all-cause mortality compared to pSmad2+, increasing its statistical significance (RR, 1.65; 95% CI,
1.24–2.18; p < 0.001; I2 = 4%) (Table 1, Figure 3).
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2.4. Publication Bias and Meta-Regression Analyses
There was no risk of publication bias for both analyzed indexes, i.e., unadjusted RR for survival
(Egger’s test, 8.62 ± 12.51, p = 0.54) and adjusted estimates (Egg r’s test, −2.28 ± 2.83, p = 0.48).
There was high heterogeneity only for (unadjusted) RR of all-cause mortality and, therefore we
investigated if d fferences in TNM III-IV or G3 prevalence between Smad2+ and Smad2- could be
significant moderators of the heterogeneity found. Neith r the differ ce in stage, as measured by TNM
III-IV between the wo groups (slope = 0.005 ± 0.008; p = 0.55) or grading, mea ured as the prevalence
in G3 cancers (slope = 0.02 ± 0.006; p = 0.09), were moderators of the heterogeneity.
3. Discussion
The present meta-analysis investigating the prognostic role of pSmad2 in gastrointestinal cancers,
found a statistically signific nt a sociation between the absence of pSmad2+ (pSmad2-) and an i creased
risk of m rtality. This finding appears robust also consideri g that th ass ciation of pSmad2- and risk
of mo t lity ha been c nfirmed using ata from multivariate analyses. The independent prognostic
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Smad2 is a specific intracellular mediator of TGF-β signaling and plays a pivotal role in
the antiproliferative effects of this pathway [18]. A seminal paper in this field pointed out that
the level of pSmad2 is inversely associated to histological differentiation in head and neck tumors [24],
indicating a potential prognostic role of the loss of this marker as an indicator of poor prognosis.
In our meta-analysis, pSMAD2- confirms its clinical value, being associated with a higher risk of
mortality also considering potential confounders. However, the biological basis of this association is
not well understood.
First, it is important to consider that, in the TGF-β signaling, Smad2 is activated by phosphorylation
upon activation of the TGF-β receptor [25]. Notably, in this meta-analysis we have considered studies
that have taken into account only the C-terminally phosphorylated Smad2, since different sites of
phosphorylation may result in totally different biological functions. The levels of pSmad2 may
directly reflect TGF-β-induced growth inhibitory/anti-proliferative effects [18,26]. Unresponsiveness
to TGF-β-induced growth inhibition as a direct result of the lack of pSmad2 may have different effects
in cancer biology, from the stimulation of tumor development and growth to distant metastasization.
Notably, the phosphorylation of Smad2 is the most important step for this factor to control its function,
and this explains that the vast majority of cancers with an impaired Smad2 action have only a dysregulated
Smad2 phosphorylation and do not present a matched SMAD2 driver gene mutation [12,27]. Indeed, this
gene has a low rate of mutations in gastrointestinal cancers, particularly if compared with its counterpart
SMAD4, which is one of the most important driver genes in gastroentero-pancreatic tumors [28–31].
Another important aspect to be considered in interpreting the present results on the negative
prognostic role of pSmad2- in gastrointestinal cancers regards the process of epithelial-to-mesenchymal
transition (EMT). EMT is a cell mechanisms in which the epithelial elements lose their polarity
and cell-to-cell contacts, undergo remodeling of the cytoskeleton with morphological modifications,
acquiring also motility and migratory capacities [32]. Particularly, in cancer biology and in several
cancer types, EMT is a fundamental process for tumor development and metastasization [33–37].
Particularly, EMT via TGF-β/Smad pathway has been investigated in different cancer types [38–41],
where TGF-β emerges as a tumor suppressor in the early stages of tumorigenesis, whereas in later
stages it may favor tumor progression and metastatization via EMT activation [17,21,42,43]. In later
stages, indeed, tumor cells may undergo EMT through TGF-β signaling, becoming more invasive
and with greater metastatic potential. TGF-β suppresses immune responses of non-transformed cancer
cells, increasing neo-angiogenesis and leading to progression, metastasis and even to the unfavorable
prognostic event of extranodal extension of nodal metastasis [17,21,42–49]. All these events may
explain, at least partly, the biological reasons of the negative prognostic role of pSmad2- that has been
demonstrated with this meta-analysis. The switching of TGF-β signaling from a tumor suppressor
to a tumor promoter is essential to better understanding this specific step in the complex process
of tumorigenesis.
Although the finding of a correlation of the absence of pSmad2 expression with a worse prognosis
seems to contradict the general assumption that enhanced TGF-beta signaling activity favors tumor
progression in late tumor stages, one possible further explanation is that tumor progression is driven by
pSmad3, rather than pSmad2, and that pSmad2 acts as an endogenous inhibitor of the tumor-promoting
function of pSmad3.
In this line, it is also of importance considering the role of Smad3 in the complex interaction of
TGF-β pathway with EMT. Smad3 indeed has been demonstrated as an important mediator in such
interaction. For example, renal tubular epithelial cells deficient in Smad3 fail to undergo EMT in
response to TGF-β or mechanical stress, and keratinocytes from Smad3–/– mice demonstrate reduced
migration in response to TGF-β [50]. Compared with Smad3, Smad2 may play an antagonistic role
in the EMT process in vivo: In fact, loss of Smad2 has been frequently shown in human skin cancers,
and Smad2 deficiency in keratinocytes promotes EMT accelerating skin tumorigenesis [50]. This has
been explained by increased binding of the Smad3/4 complex to the promoter of the SNAIL gene and by
increased SNAIL expression in the absence of Smad2, thus enhancing the progression of EMT [50].
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In a similar way, also highlighting that Smad2 is important in different tissues, Smad2–/– hepatocytes
appear mesenchymal and migrate faster than wild-type cells, whereas Smad3–/– hepatocytes retain
their epithelial features [50].
Although the results of this systematic review with meta-analysis appears reliable, we recognize in
it also some limitations, which are largely reflected by those within the primary studies. First, the design
of the studies included in the present review were retrospective; moreover, in these studies, data about
other co-morbidities (like cardio-vascular diseases) were not specifically considered, but it is known that
such comorbidities also play an important clinical role in patients with cancer. A final limitation includes
the high heterogeneity found for the unadjusted relative risk for all-cause mortality. However, using data
from multivariable models, the heterogeneity became low and at the same time the statistical significance
of the present results was preserved, further corroborating the reliability of the finding.
In conclusion, with this meta-analysis it has been demonstrated that lack of pSmad2 is strongly
associated with an increased risk of mortality in gastrointestinal cancers. This finding highlights
the importance of the TGF-β signaling in cancer. Further studies are now needed to explore more in
depth this molecular pathway and also possible therapeutic strategies, taking into account its potential
effectors or molecular targets.
4. Materials and Methods
This systematic review adhered to the Meta-analyses Of Observational Studies in Epidemiology
(MOOSE) guidelines and Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement, following a predetermined protocol [51,52].
4.1. Inclusion and Exclusion Criteria
Studies were eligible for inclusion upon meeting the following criteria: (1) a prospective cohort
or retrospective study design; (2) it contained a comparison of prognostic factors between positive vs.
negative pSmad2 with immunohistochemistry; (3) it considered only C-terminally phosphorylated Smad2;
(4) a diagnosis of conventional gastrointestinal cancers; (5) it contained data about mortality/recurrence
of disease; (6) it was published in a peer review journal or published abstract. Articles in any language
were considered.
Exclusion criteria were: (1) no presence of specific data on pSma2, (2) no clear standards of
immunohistochemical protocol and its interpretation, (3) no data about prognostic parameters in
the title/abstract, (4) no comparison between positive vs. negative pSmad2 patients, and (5) in vitro or
animal studies.
We selected research papers that investigated Smad2 with immunohistochemistry since this is
the best method to study the effective Smad2 function, given that SMAD2 mutations are very rare in
gastrointestinal cancers and do not represent a reliable indicator of Smad2 activity.
4.2. Data Sources and Literature Search Strategy
Two investigators (I.G., N.V.) independently searched PubMed, Embase and SCOPUS until
05/31/2019. The search terms used in PubMed included combinations of the following keywords:
(SMAD2 OR JV18 OR JV18-1 OR MADH2 OR MADR2 OR hMAD-2 OR hSMAD2) AND (cancer OR
neoplasm OR neoplasia OR carcinoma OR adenocarcinoma) AND (mortality OR mortalities OR
fatality OR fatalities OR death* OR survival OR “hazard ratio” OR HR OR “relative risk” OR RR OR
progression OR recurrence). A similar research was made in SCOPUS and Embase. We considered
the reference lists of all included articles and of previous related reviews.
4.3. Study Selection
Following the searches as outlined above, after removal of duplicates, two independent reviewers
(I.G., L.S.) screened titles and abstracts of all potentially eligible articles. The two authors applied
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the eligibility criteria, considered the full texts, and a final list of included articles was reached through
consensus with a third author (A.N.).
4.4. Data Extraction
Two authors were involved in data extraction in a standardized Microsoft Excel database.
Specifically, one author (N.V.) extracted data from the included articles and a second independent author
(A.N.) validated the data. For each article, the following information was extracted: Authors, year of
publication, country, exclusion criteria, other genes/proteins abnormalities that have been studied in
the specific work, number of participants and gender, age, pathologic TNM stage, tumor grading,
type of IHC analysis (whole section vs. tissue micro-array), number of adjustments in survival analyses
and duration of follow-up.
4.5. Outcomes
The primary outcome was the number of deaths after treatment during the follow-up period
in patients with positive vs. negative pSmad2. The secondary outcome was the risk, adjusted for
the maximum number of confounders available in each paper, regarding the same outcome, taking those
with positive pSmad2 as reference.
4.6. Assessment of Study Quality
We used the Newcastle-Ottawa Scale (NOS) to evaluate study quality [53]. The NOS provides
an assessment of the methodological quality of observational studies and its content validity
and reliability have been widely assessed [54]. Included studies are assessed on 8 items across three
key areas: selection of the participants, comparability of the participants and outcomes. Two authors
(A.N., N.V.) completed the NOS and each study received an overall score for methodological quality of
up to 9 points with a score of ≤5 (out of 9) indicating high risk of bias.
4.7. Data Synthesis and Statistical Analysis
All analyses were performed using Comprehensive Meta-Analysis (CMA) 2 (Biostat, Englewood,
NJ, USA). In our primary analyses, pooled risk ratios (RRs) and 95% confidence intervals (CIs) of risk
of mortality between positive pSmad2 vs. negative pSmad2 were calculated using DerSimonian-Laird
random-effects models [55]. In secondary analyses, pooled hazard ratios (HRs) with 95% CIs adjusted
for the maximum number of covariates available in the articles were also calculated for providing
additional information if the relationship between pSmad2 status and survival was influenced by
potential confounders. Heterogeneity across studies was assessed by the I2 metric and chi square
statistics [56]. In the presence of significant heterogeneity (p < 0.05) after removing outlier studies,
a series of meta-regression analyses according to pSmad2 status and each of prognostic parameters
were considered. Finally, publication bias was investigated for the primary meta-analysis with a visual
inspection of funnel plots coupled with the Egger bias test [57].
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/15/
3831/s1. Figure S1. PRISMA checklist for this meta-analysis; Table S1. Characteristics of The Studies According to
the Expression of SMAD2; Table S2. Methodological Quality of Cohort Studies Included in the Meta-Analysis;
Table S3. Type and number of adjustments (in addiction of pSMAD2 status) for each study.
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